NORMALIZATION OF INVITRO SENSITIVITY TESTING OF HUMAN-TUMOR CLONOGENIC CELLS

Abstract

The use of normal bone marrow (granulocyte-macrophage colony-forming units) as a point of reference to normalize the in vitro activities of anticancer agents was investigated. The cytotoxic effects of 4 substituted anthraquinone derivatives [Adriamycin, 4-epidoxorubicin, dihydroxyanthracenedione, 9,10-anthracenedicarboxyaldehyde], and of vinblastine on myeloid progenitors of different donors were reproducible up to a cell kill of .apprx. 60%. Equitoxic in vitro concentrations for normal bone marrows did not correlate with in vivo pharmacokinetic concentrations of these drugs. Breast tumor progenitor cells of 46 specimens were more sensitive than were bone marrow progenitors to the anthraquinone derivatives in 26-39% of instances, ratios which are similar to the clinically observed response rates of patients with breast carcinoma to these agents. Tumors were either sensitive or resistant to all 4 drugs in 68% (10 tumors were more sensitive, and 21 tumors were less sensitive than normal bone marrow); but in 32% of instances there were differences in tumor sensitivity for the 4 drugs, and the assay could select one to three drugs for which the tumor sensitivity was greater than that of bone marrow. Correlations of in vitro sensitivity and of clinical response to single agent treatments were determined in 21 patients, and the concordance was 71%. The value of the assay in predicting clinical response ranked best for sensitivity determinations within the normalized dose ranges, when testing within 3 dose ranges was compared in a group of 6 patients. The concordance was higher in the small (1 or 2 metastatic sites) than in the large (.gtoreq. 3 metastatic sites) tumors (85 vs. 50%), indicating a confounding influence of tumor load on the ability of the assay to predict efficacy of treatment. A rule of thumb is proposed for altering the in vitro sensitivity test results for large tumors that improves the overall concordance to 90%.